<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27306" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Plasmapheresis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sergent</surname>
            <given-names>Shane R.</given-names>
          </name>
          <aff>Michigan State University College of OM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashurst</surname>
            <given-names>John V.</given-names>
          </name>
          <aff>Kingman Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shane Sergent declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Ashurst declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27306.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Plasmapheresis is a therapeutic intervention that involves extracorporeal removal, return, or exchange of blood plasma or components. The underlying mechanism of this procedure is accomplished by either centrifugation or filtration using semipermeable membranes. This activity reviews plasmapheresis as a therapeutic intervention that involves extracorporeal removal, return, or exchange of blood plasma or components. This intervention results in a filtered plasma product that can be used for the treatment of numerous diseases. It also highlights the interprofessional team strategies for improving care coordination and communication to advance plasmapheresis and improve outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications and contraindications of plasmapheresis.</p></list-item><list-item><p>Describe the equipment, personnel, preparation, and technique in regards to plasmapheresis.</p></list-item><list-item><p>Review the potential complications and clinical significance of plasmapheresis.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance plasmapheresis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27306">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27306.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Plasmapheresis is a therapeutic intervention that involves extracorporeal removal, return, or exchange of blood plasma or components.<xref ref-type="bibr" rid="article-27306.r1">[1]</xref><xref ref-type="bibr" rid="article-27306.r2">[2]</xref>&#x000a0;The underlying mechanism of this procedure is accomplished by either centrifugation or filtration using semipermeable membranes. While centrifugation is based on the principle of separation using different specific gravities of various blood components, membrane plasma separation filters blood components based on their particle size.<xref ref-type="bibr" rid="article-27306.r3">[3]</xref><xref ref-type="bibr" rid="article-27306.r4">[4]</xref></p>
        <p>The preferred method of plasmapheresis in most centers&#x000a0;worldwide is by automated centrifuge-based technology.<xref ref-type="bibr" rid="article-27306.r5">[5]</xref>&#x000a0;However, in certain hospitals and patients on hemodialysis, plasmapheresis is done using membrane plasma separation.<xref ref-type="bibr" rid="article-27306.r3">[3]</xref>&#x000a0;In plasmapheresis using centrifugation, filtered plasma is discarded, and RBCs and replacement fluid (donor plasma or colloids) are returned. Membrane plasma separation allows selective removal of undesired macromolecules; hence, filtered, processed plasma is returned to the patient, eliminating the need for replacement fluids.</p>
        <p>In this review, we will discuss the indications, contraindications, equipment, preparation, procedure, and complications of plasmapheresis.</p>
      </sec>
      <sec id="article-27306.s3" sec-type="Indications">
        <title>Indications</title>
        <p>Therapeutic plasmapheresis is used for numerous diseases. The conditions involve the presence of a toxic substance in plasma (e.g., immunoglobulin), which can be filtered. The disorders where therapeutic plasmapheresis can be done are grouped into four categories by the Apheresis Applications Committee of the American Society for Apheresis (ASFA). Category 1 includes disorders where plasmapheresis can be done as a first-line treatment, category 2 includes disorders where plasmapheresis can be done as a second-line treatment in addition to the existing standard of care, category 3 includes disorders in which the evidence of the benefit of plasmapheresis is minimal, and therapy must be individualized, and category 4 includes disorders in which the evidence suggests that plasmapheresis is either ineffective or harmful, however, may be considered after approval from the institute ethics committee.<xref ref-type="bibr" rid="article-27306.r2">[2]</xref></p>
        <p>The alphabetical list of various indications for plasmapheresis, along with their ASFA category, is as follows.</p>
        <p>Category 1</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute inflammatory demyelinating polyradiculoneuropathy/Guillain-Barre syndrome</p>
          </list-item>
          <list-item>
            <p>ANCA-associated rapidly progressive glomerulonephritis (dialysis-dependent or associated with diffuse alveolar hemorrhage)</p>
          </list-item>
          <list-item>
            <p>Anti-glomerular basement membrane disease-Goodpasture syndrome (dialysis independent or associated with diffuse alveolar hemorrhage)</p>
          </list-item>
          <list-item>
            <p>Chronic inflammatory demyelinating polyradiculoneuropathy</p>
          </list-item>
          <list-item>
            <p>Focal segmental glomerulosclerosis (recurrent in the transplanted kidney)</p>
          </list-item>
          <list-item>
            <p>Hyperviscosity in monoclonal gammopathies</p>
          </list-item>
          <list-item>
            <p>Liver transplantation: Desensitization</p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis</p>
          </list-item>
          <list-item>
            <p>N-methyl D-aspartate receptor antibody encephalitis</p>
          </list-item>
          <list-item>
            <p>Paraproteinemic demyelinating neuropathies/chronic acquired demyelinating polyneuropathies (IgA/IgG/IgM mediated)</p>
          </list-item>
          <list-item>
            <p>Progressive multifocal leukoencephalopathy associated with natalizumab</p>
          </list-item>
          <list-item>
            <p>Renal transplantation: Desensitization and antibody-mediated rejection</p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy (Factor H autoantibodies and ticlopidine)</p>
          </list-item>
          <list-item>
            <p>Thrombotic thrombocytopenic purpura</p>
          </list-item>
          <list-item>
            <p>Wilson disease (fulminant)</p>
          </list-item>
        </list>
        <p>Category 2</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute disseminated encephalomyelitis</p>
          </list-item>
          <list-item>
            <p>Cardiac transplantation: Desensitization</p>
          </list-item>
          <list-item>
            <p>Catastrophic antiphospholipid syndrome</p>
          </list-item>
          <list-item>
            <p>Cryoglobulinemia; symptomatic/severe</p>
          </list-item>
          <list-item>
            <p>Dilated cardiomyopathy, idiopathic (NYHA 2-4)</p>
          </list-item>
          <list-item>
            <p>Hashimoto encephalopathy: Corticosteroid responsive encephalopathy associated with autoimmune thyroiditis</p>
          </list-item>
          <list-item>
            <p>Hematopoietic stem cell transplantation, ABO-incompatible</p>
          </list-item>
          <list-item>
            <p>Lambert-Eaton myasthenic syndrome</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Myeloma cast nephropathy</p>
          </list-item>
          <list-item>
            <p>Neuromyelitis Optica spectrum disorders</p>
          </list-item>
          <list-item>
            <p>Overdose, envenomation, and poisoning, such as mushroom</p>
          </list-item>
          <list-item>
            <p>Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)</p>
          </list-item>
          <list-item>
            <p>Phytanic acid storage disease (Refsum disease)</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus (severe)</p>
          </list-item>
        </list>
        <p>Category 3</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute liver failure</p>
          </list-item>
          <list-item>
            <p>ANCA-associated rapidly progressive glomerulonephritis (dialysis independent)</p>
          </list-item>
          <list-item>
            <p>Anti-glomerular basement membrane disease, Goodpasture syndrome (dialysis-dependent, no DAH)</p>
          </list-item>
          <list-item>
            <p>Aplastic anemia, pure red cell aplasia</p>
          </list-item>
          <list-item>
            <p>Autoimmune hemolytic anemia</p>
          </list-item>
          <list-item>
            <p>Burn shock resuscitation</p>
          </list-item>
          <list-item>
            <p>Cardiac neonatal lupus</p>
          </list-item>
          <list-item>
            <p>Cardiac transplantation: Antibody-mediated rejection</p>
          </list-item>
          <list-item>
            <p>Chronic focal encephalitis (Rasmussen encephalitis)</p>
          </list-item>
          <list-item>
            <p>Complex regional pain syndrome; chronic</p>
          </list-item>
          <list-item>
            <p>Erythropoietic porphyria, liver disease</p>
          </list-item>
          <list-item>
            <p>Hemolysis liver enzymes low platelet (HELLP) syndrome (postpartum)</p>
          </list-item>
          <list-item>
            <p>Hematopoietic stem cell transplantation, HLA desensitization</p>
          </list-item>
          <list-item>
            <p>Hemophagocytic lymphohistiocytosis; hemophagocytic syndrome; macrophage activating syndrome</p>
          </list-item>
          <list-item>
            <p>Henoch-Schonlein purpura</p>
          </list-item>
          <list-item>
            <p>Heparin-induced thrombocytopenia and thrombosis</p>
          </list-item>
          <list-item>
            <p>Hypertriglyceridemic pancreatitis</p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia; refractory</p>
          </list-item>
          <list-item>
            <p>IgA nephropathy; crescentic</p>
          </list-item>
          <list-item>
            <p>Lung transplantation: Desensitization and antibody-mediated rejection</p>
          </list-item>
          <list-item>
            <p>Paraneoplastic neurological syndromes</p>
          </list-item>
          <list-item>
            <p>Pemphigus Vulgaris; severe</p>
          </list-item>
          <list-item>
            <p>Pruritus due to hepatobiliary diseases</p>
          </list-item>
          <list-item>
            <p>Scleroderma (systemic sclerosis)</p>
          </list-item>
          <list-item>
            <p>Sepsis with multiorgan failure</p>
          </list-item>
          <list-item>
            <p>Stiff-person syndrome</p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy (complement factor gene mutations, MCP mutations, clopidogrel, and calcineurin inhibitors)</p>
          </list-item>
          <list-item>
            <p>Thyroid storm</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis (refractory)</p>
          </list-item>
          <list-item>
            <p>Vasculitis</p>
          </list-item>
          <list-item>
            <p>Voltage-gated potassium channel antibodies</p>
          </list-item>
        </list>
        <p>Category 4</p>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis, systemic</p>
          </list-item>
          <list-item>
            <p>Dermatomyositis/polymyositis</p>
          </list-item>
          <list-item>
            <p>HELLP syndrome (antepartum)</p>
          </list-item>
          <list-item>
            <p>Lupus nephritis</p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy (gemcitabine and quinine)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27306.s4" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The contraindications for therapeutic plasmapheresis are as follows:<xref ref-type="bibr" rid="article-27306.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Non-availability of central line access or large bore peripheral lines</p>
          </list-item>
          <list-item>
            <p>Hemodynamic instability or septicemia</p>
          </list-item>
          <list-item>
            <p>Known allergy to fresh frozen plasma or replacement colloid/albumin</p>
          </list-item>
          <list-item>
            <p>Known allergy to heparin</p>
          </list-item>
          <list-item>
            <p>Hypocalcemia (restricts the use of citrate as an anticoagulant during the procedure); relative contraindication</p>
          </list-item>
          <list-item>
            <p>Angiotensin-converting enzyme (ACE) inhibitor used in last 24 hours; relative contraindication</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27306.s5" sec-type="Equipment">
        <title>Equipment</title>
        <p>Venous access for this procedure is either by a central venous catheter or large bore peripheral lines. There are multiple manufacturers of the centrifuge-based plasmapheresis machines.</p>
        <p>Another technique of performing plasmapheresis is by using semipermeable membrane filters with a standard hemodialysis machine. However, for this technique, central venous access is mandatory due to the need for higher blood flow rates of 100 mL/min to 150 mL/min. There are two membrane-based technologies that are currently available; hollow fiber and parallel plate. Hollow fiber dialyzers are cylindrical shell-like structures, consisting of multiple polysulfone capillary fibers.</p>
        <p>Parallel plate dialyzers consist of layered membranes, with ridges and grooves which facilitate filtration. Both these dialyzers allow plasma filtration based on particle size and pressure gradients. Hollow fiber dialyzers are more gentle as opposed to parallel plate dialyzers and are preferred for pediatric patients, whereas hollow fiber dialyzers use less blood volume, and hence require a reduced dose of citrate or heparin for anticoagulation.</p>
        <p>The major advantage of membrane-based plasmapheresis over centrifuge-based technology is that the removed processed-plasma by ultrafiltration can be returned to the patient eliminating the need for replacement fluids or colloids.<xref ref-type="bibr" rid="article-27306.r1">[1]</xref></p>
      </sec>
      <sec id="article-27306.s6" sec-type="Personnel">
        <title>Personnel</title>
        <p>Plasmapheresis was traditionally performed in blood banks by centrifuge-based techniques. However, therapeutic plasmapheresis procedures are routinely performed by critical care specialists in the intensive care unit, nephrologists, and dialysis-technicians after specialized skill-based training.</p>
      </sec>
      <sec id="article-27306.s7" sec-type="Preparation">
        <title>Preparation</title>
        <p>No specific patient preparation is needed for this procedure. However, while inserting a central line, a local anesthetic may be needed. For this purpose, 2% lidocaine injection is used routinely. In pediatric patients, sedation with opioids and benzodiazepines may be considered for pain and anxiety control.</p>
        <p>The patient is positioned supine for plasmapheresis; however, the position, especially of the neck, may be altered according to the location of central venous access to maintain adequate blood flow throughout the procedure.</p>
        <p>A close watch on patient vitals is recommended throughout the procedure to assess for volume depletion, hypocalcemia, and complications of fresh frozen plasma transfusion.</p>
      </sec>
      <sec id="article-27306.s8" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>The steps for performing plasmapheresis using centrifuge-based equipment are as follows:<xref ref-type="bibr" rid="article-27306.r6">[6]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Initially, a waste of around 3-5 mL blood from the central venous catheter is discarded.</p>
          </list-item>
          <list-item>
            <p>After drawing baseline samples for complete hemogram, calcium, and fibrinogen, it is flushed with 5-10 mL of heparinized saline.</p>
          </list-item>
          <list-item>
            <p>The double lumen catheter is now connected to the machine tubing to start the priming procedure.</p>
          </list-item>
          <list-item>
            <p>The machine calculates total body volume (TBV), and the effective plasma volume (which equals&#x000a0;TBV &#x000d7; (1 &#x02013; hematocrit)) of the patient based on the operator entered height and weight.</p>
          </list-item>
          <list-item>
            <p>The replacement product to be used and its desired volume (40 - 60 mL/kg) is decided by the clinician, and entered into the machine, based on which it calculates the centrifuge speed.</p>
          </list-item>
          <list-item>
            <p>The separated plasma is discarded by the machine, and the RBCs are returned back to the patient along with the replacement fluid.</p>
          </list-item>
          <list-item>
            <p>Finally, post-procedure, tubings are connected to heparinized saline, and reinfusion is initiated.</p>
          </list-item>
          <list-item>
            <p>Post-plasmapheresis blood for fibrinogen and calcium is sent again, and lumens of central venous catheters are flushed.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27306.s9" sec-type="Complications">
        <title>Complications</title>
        <p>The common complications that can occur during or post-plasma exchange procedure are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypocalcemia or hypomagnesemia as a result of the use of citrate anticoagulation. This is managed with the intravenous replacement of calcium and magnesium.<xref ref-type="bibr" rid="article-27306.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Hypothermia</p>
          </list-item>
          <list-item>
            <p>Transfusion reactions. They are managed symptomatically with pheniramine, hydrocortisone/dexamethasone, and/or epinephrine.</p>
          </list-item>
          <list-item>
            <p>Fluid and electrolyte imbalance.</p>
          </list-item>
          <list-item>
            <p>Bleeding diatheses due to hypofibrinogenemia and thrombocytopenia.</p>
          </list-item>
          <list-item>
            <p>Hypotension<xref ref-type="bibr" rid="article-27306.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms like nausea and vomiting</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27306.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Plasmapheresis offers an effective therapy for many acute and chronic diseases. It can also be used as an adjunct to prepare for procedures, surgery, and even improve postoperative recovery or shorten ventilation periods. Generally, risks and side effects are mild, most common being transient hypotension and related symptoms.<xref ref-type="bibr" rid="article-27306.r9">[9]</xref><xref ref-type="bibr" rid="article-27306.r10">[10]</xref></p>
        <p>The American Society for Apheresis has done extensive research on plasmapheresis as a therapeutic strategy, and continue to update a comprehensive apheresis guideline using an evidence-based approach to aid physicians caring for these patients.<xref ref-type="bibr" rid="article-27306.r10">[10]</xref>&#x000a0;Using this evidence-based resource is the best way to standardize care and provide innovation.<xref ref-type="bibr" rid="article-27306.r9">[9]</xref><xref ref-type="bibr" rid="article-27306.r10">[10]</xref></p>
      </sec>
      <sec id="article-27306.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Plasmapheresis is an intensive care procedure that needs appropriate decisions, specialized skill-based training, close monitoring, and follow-up for best clinical outcomes. It is recommended that a customized dedicated chart must be designed at all centers performing plasmapheresis procedures. This should include a brief history, with established/presumptive diagnosis.</p>
        <p>The basis for the procedure, along with patient-specific concerns, must be listed. This chart should also indicate the total number of plasmapheresis sessions planned. The healthcare professionals must clearly discuss the clinical and/or laboratory parameters to monitor the effectiveness of the procedure and enlist criteria for completion/discontinuation. The urgency of the procedure (emergency, urgent, or routine) must be delineated while planning for plasmapheresis. These holistic goals can ensure the effectiveness and reduce complications of plasmapheresis in clinical settings.</p>
      </sec>
      <sec id="article-27306.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27306">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27306/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27306">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27306.s13">
        <title>References</title>
        <ref id="article-27306.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange: core curriculum 2008.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1180</fpage>
            <page-range>1180-96</page-range>
            <pub-id pub-id-type="pmid">18562061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Padmanabhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aqui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Balogun</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Connelly-Smith</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shaz</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.</article-title>
            <source>J Clin Apher</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>149</fpage>
            <page-range>149-62</page-range>
            <pub-id pub-id-type="pmid">27322218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerhardt</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Ntoso</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Koethe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lodge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Acute plasma separation with hemodialysis equipment.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>9</issue>
            <fpage>1455</fpage>
            <page-range>1455-8</page-range>
            <pub-id pub-id-type="pmid">1627768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siami</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Siami</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Membrane plasmapheresis in the United States: a review over the last 20 years.</article-title>
            <source>Ther Apher</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-20</page-range>
            <pub-id pub-id-type="pmid">11724518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurland</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lysaght</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Samtleben</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A comparison of centrifugal and membrane-based apheresis formats.</article-title>
            <source>Int J Artif Organs</source>
            <year>1984</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-8</page-range>
            <pub-id pub-id-type="pmid">6698631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Staley</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange - A brief review of indications, urgency, schedule, and technical aspects.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-246</page-range>
            <pub-id pub-id-type="pmid">31085053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mokrzycki</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange: complications and management.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>817</fpage>
            <page-range>817-27</page-range>
            <pub-id pub-id-type="pmid">8203364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owen</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Brecher</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis.</article-title>
            <source>Transfusion</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>891</fpage>
            <page-range>891-4</page-range>
            <pub-id pub-id-type="pmid">7940662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Carcillo</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The role of plasmapheresis in critical illness.</article-title>
            <source>Crit Care Clin</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>453</fpage>
            <page-range>453-68, vii</page-range>
            <pub-id pub-id-type="pmid">22713617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27306.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szczepiorkowski</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bandarenko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Linenberger</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Sarode</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shaz</surname>
                <given-names>BH</given-names>
              </name>
              <collab>Apheresis Applications Committee of the American Society for Apheresis</collab>
            </person-group>
            <article-title>Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.</article-title>
            <source>J Clin Apher</source>
            <year>2010</year>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>83</fpage>
            <page-range>83-177</page-range>
            <pub-id pub-id-type="pmid">20568098</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
